Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial“In summary, our study indicates that early ToD immunochemotherapy substantially improves PFS and OS and is associated with enhanced antitumor CD8+ T cell characteristics compared...
Osimertinib Dose Reduction Does Not Compromise OS in EGFR-Mutated Metastatic NSCLC“Reducing osimertinib dose in the first-line treatment of EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) patients due to the occurrence of adverse events has no impact on...
Lung cancer deaths leveling off for EU women, except in Spain“Now, in a new study published in the leading cancer journal Annals of Oncology today (Monday), researchers led by Carlo La Vecchia (MD), Professor of Medical Statistics and Epidemiology at the University of...
Lung Cancer Research Foundation and Oncology Advocates United for Climate and Health – International Announce Request for Proposals Now Open for Submission“NEW YORK, Jan. 12, 2026 /PRNewswire/ — The Lung Cancer Research Foundation (LCRF) and Oncology...
Lung Cancer Research Foundation Announces Additional 2025 Scientific Research Grant Awards“NEW YORK, Jan. 6, 2026 /PRNewswire/ — The Lung Cancer Research Foundation® (LCRF) recently awarded five new research grants in the following areas: three LCRF Leading-Edge...
More News and Updates